Increasing the infliximab dose is beneficial in Crohn's disease patients who responded to a lower dose and relapsed

Yoram Menachem, Benjamin Avidan, Alexandra Lavy, Alon Lang, Eytan Bardan, Herma Fidder, Simon Bar-Meir, Yehuda Chowers

Research output: Contribution to journalArticlepeer-review


Background: Relapse after an initial response to infliximab therapy poses a problem for maintenance treatment. Aim: To assess the effects of increasing the infliximab dosage in Crohn's disease (CD) patients who initially responded but flared during maintenance therapy. Methods: This was an observational study. Twelve CD patients with both inflammatory and fistulizing manifestations were included. All patients initially responded to 5 mg/kg of infliximab, relapsed during maintenance therapy, and were treated with 10 mg/kg. The Harvey-Bradshaw index, the fistula activity, and steroid use were assessed before and after treatment with the increased dose of infliximab. Results: The mean Harvey-Bradshaw index score after flare-up during treatment with 5 mg/kg of infliximab was 13.5 ± 3.7. Treatment with 10 mg/kg, in a mean of 3.3 infusions, decreased the activity score to a mean of 8.8 ± 2.5. Two patients were weaned off prednisone, and a reduced dose was possible in the other steroid-treated patients. Conclusions: Increasing the infliximab dose may be beneficial in CD patients who initially responded to therapy, but relapsed during maintenance with the lower dosage.

Original languageEnglish
Pages (from-to)124-128
Number of pages5
Issue number2-3
StatePublished - 2005
Externally publishedYes


  • CD, inflammatory and fistulizing
  • Crohn's disease
  • Infliximab
  • Relapse in CD patients


Dive into the research topics of 'Increasing the infliximab dose is beneficial in Crohn's disease patients who responded to a lower dose and relapsed'. Together they form a unique fingerprint.

Cite this